MedTrace Logo

Surgical Ward Innovation: Telemonitoring Controlled by Healthdot

NCT05956210 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-07-21

No results posted yet for this study

Summary

This observational clinical, single center trial is designed to evaluate the implementation of an already validated smart monitoring device, the Philips Healthdot, on one surgical ward at the Catharina hospital in Eindhoven, The Netherlands.

This study is performed during 6 months in which all patients admitted to one surgical ward will be enrolled. Implementation is established by a step-by-step approach in which the current manually performed spot check monitoring (blood pressure, oxygen saturation, respiratory rate, heart rate, temperature and pain score), with the early warning score (EWS), is continued besides smart monitoring with the Healthdot (respiratory rate, heart rate and physical activity) during the first three months (phase 1). This phase aims at optimizing the infrastructure, education of hospital staff and practice with application/ activation and interpretation of the device. Upward of 4 months, Healthdot monitoring will be the primary monitoring method and spot check monitoring is only performed additionally in case of doubt about clinical condition or requirement of additional vital parameters.

Evaluation of the implementation will be performed with a focus group and various questionnaire regarding fidelity, acceptability, adoption, feasibility, appropriateness and costs. Thereby additional analysis regarding monitoring algorithms will be performed.

Conditions

  • Monitoring

Interventions

DEVICE

Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward

Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation

Sponsors & Collaborators

  • Philips Electronics Nederland B.V. acting through Philips CTO organization

    collaborator INDUSTRY

  • Catharina Ziekenhuis Eindhoven

    lead OTHER

Principal Investigators

  • Friso Schonck · Catharina Ziekenhuis Eindhoven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-10-01
Completion
2023-11-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05956210 on ClinicalTrials.gov